Pay in 4 interest-free payments of $7.49 Learn more
Ships within 48 hours · Estimated delivery Oct 7 - Oct 12
Primary candidates for GLP-1 therapy include: Patients with type 2 diabetes and inadequate glycemic control despite metformin therapy Individuals with type 2 diabetes and established atherosclerotic cardiovascular disease Patients with type 2 diabetes and multiple cardiovascular risk factors (hypertension, dyslipidemia, obesity) Adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities Patients with metabolic syndrome who have not achieved adequate risk factor control with lifestyle modification For patients with dyslipidemia, GLP-1 agents may be particularly valuable when combined with statin therapy in those who have not reached LDL-C goals or who have persistent hypertriglyceridemia despite statin treatment
Takotsubo cardiomyopathy may develop
Sip water frequently
The study was a double-blind, placebo-controlled trial with participants receiving once-weekly subcutaneous doses of tirzepatide or a placebo
Warner said it was "disappointing" the injection had not been recorded at the time by the doctor
US$ 24.38
US$ 26.89
US$ 21.77
US$ 23.52
US$ 20.64
US$ 29.67
US$ 28.31
US$ 20.74
US$ 28.95
